Table 2.

The proportions of platelets present with the indicated triple marker phenotypes, based on annexin-V (AnnV), CD42b and CD62P.

	Fluorescent marker combination (%)
	AnnV−				AnnV+
Treatment group	CD42b+ CD62P−	CD42b+ CD62P+	CD42b− CD62P−	CD42b− CD62P+	CD42b+ CD62P−	CD42b+ CD62P+	CD42b− CD62P−	CD42b− CD62P+
Unstimulated	73 ± 9	20 ± 6	1 ± 0	0 ± 0	0 ± 0	2 ± 1	0 ± 0	0 ± 0
C&T	2 ± 0	62 ± 10	2 ± 1	1 ± 1	3 ± 1	29 ± 8	1 ± 0	0 ± 0
A23187	2 ± 1	6 ± 6	1 ± 1	0 ± 0	17 ± 11	72 ± 9	1 ± 1	1 ± 1
ABT-737	0 ± 0	0 ± 0	1 ± 0	1 ± 0	0 ± 0	0 ± 0	90 ± 3	7 ± 3
Cryopreserved	6 ± 4	11 ± 5	2 ± 1	0 ± 0	56 ± 8	23 ± 7	2 ± 2	0 ± 0
Subpopulation	Resting	Aggregatory	N/A	N/A	Novel	Procoagulant	Apoptotic	N/A

Data shown as mean ± SD; n = 6 in each group.

Bolded cells indicate the dominant phenotype(s) within the treatment group.

N/A indicates a minority phenotype not associated with a subpopulation.

Novel indicates a phenotype not aligned with the known subpopulations.